New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Aptar Pharma has released an industry first - PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.

New portable and ready-to-use upper respiratory drug delivery solution

PureHale was officially launched this week at CPhI Worldwide in Madrid and was a finalist in the CPhI Pharma Awards in the Excellence in Pharma: Drug Delivery Device category.

With the ongoing rise in pollution the need for upper respiratory relief is more prominent than ever. PureHale’s innovative technology distributes a continuous fine mist that gently cleanses, moisturizes and soothes the upper respiratory tract, in turn helping to reduce irritations caused by coughs, colds, allergies, respiratory problems and dry nose/throat issues.

PureHale’s portability allows consumers to relieve their symptoms wherever and whenever needed. Developed after researching and analysing the benefits and challenges of traditional nebulizer technology, this new user-friendly system was engineered for on-the-go consumers. Unlike traditional nebulizers, the PureHale system does not require batteries or the prefilling of a reservoir.

The PureHale technology platform benefits include the following:

  • Use of non-electronic technology eliminates need to plug in or charge
  • Quieter and lighter than traditional nebulizers
  • Complete portability and always ready to use
  • Includes mask and mouthpiece options, offering adaptable treatment and suitable for family use
  • Continuous cooling mist with fine particles (20-30µm) optimized for targeted deposition to the upper airways.
  • Guenter Nadler, Director Business Development at Aptar Pharma, said: “We are really excited to announce this newest Aptar Pharma innovation. We have seen a real need for a device of this kind – traditional nebulizers come with a set of challenges including complexities in setup, manual dexterity requirements and overall usage time. Meanwhile, challenges during medication administration include poor inhalation technique, duration of nebulization and understanding how to achieve optimal efficacy. PureHale has been designed specifically with these challenges in mind and offers a solution by simplifying the entire process.”

    Utilizing Aptar Pharma’s well-established Bag-on-Valve technology, the PureHale system preserves the integrity of the treatment solution while utilizing compressed air/nitrogen between the bag and can to create a continuous mist when actuated. This solution is valuable to pharmaceutical partners seeking a system that can carry a range of formulations, comes in various container sizes, while also offering differentiating and branding advantages.

    “PureHale enables pharmaceutical partners to expand their audience reach for their brand formulations, providing portable, symptomatic relief for upper respiratory system conditions,” said Thomas Klofac, President of Aptar Pharma’s Consumer Healthcare Division. PureHale provides brand differentiation via a range of personalization options and, with minimal parameter changes, existing filling processes can be easily adapted to fill PureHale. Aptar Pharma has extensive regulatory experience and this, combined with several standardized solutions, can satisfy a rapid-to-market launch objective.”

    Read More

    Related news

    CPhI Worldwide announces the winners  of the 15th Pharma Awards

    CPhI Worldwide announces the winners of the 15th Pharma Awards

    10 Oct 2018

    17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

    Read more 
    CMOs to benefit from double digit approvals for ADCs in the next 3 years

    CMOs to benefit from double digit approvals for ADCs in the next 3 years

    9 Oct 2018

    Therapeutic ADC market expected to reach $4 billion by 2023.

    Read more 
    Movement on the market reflected at CPhI Worldwide 2018

    Movement on the market reflected at CPhI Worldwide 2018

    3 Oct 2018

    Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

    Read more 
    Bioconjugation expertise and increased productivity in bio over next 5 years

    Bioconjugation expertise and increased productivity in bio over next 5 years

    28 Sep 2018

    Smaller bioreactors and high-density perfusion techniques needed as manufacturing makes significant efficiency improvements.

    Read more 
    Croda to showcase ProSilic drug delivery technology

    Croda to showcase ProSilic drug delivery technology

    25 Sep 2018

    New technology will give Croda’s customers access to the next generation of targeted and controlled drug delivery.

    Read more 
    First biomarker-based chemical allergy test launched

    First biomarker-based chemical allergy test launched

    21 Sep 2018

    GARDair removes the need for animal testing and opens a completely new market.

    Read more 
    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    18 Sep 2018

    China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

    Read more 
    Bio processing and manufacturing league table ranks US top and China bottom

    Bio processing and manufacturing league table ranks US top and China bottom

    3 Sep 2018

    US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.

    Read more 
    Innovation hindered by regulators

    Innovation "hindered by regulators"

    27 Aug 2018

    CPhI Annual Report expert sees CDMOs as potentially a source of process innovation but warns both regulator and license holders need to move past regulatory diktats.

    Read more 
    Middle East and Africa pharma economy to reach US$38.8 billion by 2021

    Middle East and Africa pharma economy to reach US$38.8 billion by 2021

    17 Aug 2018

    CPhI Middle East & Africa opens in Abu Dhabi as finished dosage formulations expand quickly, driven by government reforms to further increase local manufacturing.

    Read more